JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Therapeutic Efficacy and Neurobiological Mechanisms of Nitrous Oxide in Treatment-Resistant Depression

Syed Ansar Ahmed*[1], Aishvarya Baburao Ghayale[2], Shital Parmeshwar Hale[3], Yogita Sahebrao Dheple[4], Shaikh Alim Ahemadsab[5]

[1] *Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*
[2] *PG Scholar, Department of Pharmacology, Shrimati Latatai Baburao Patil Institute of Pharmacy, Khandgaon, Nanded, Maharashtra, India*
[3] *PG Scholar, Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Mumbai, Maharashtra, India*
[4] *PG Scholar, Department of Pharmaceutics, Shrimati Latatai Baburao Patil Institute of Pharmacy, Nanded, Maharashtra, India*
[5] *PG Scholar, Department of Pharmaceutical Quality Assurance, Shrimati Latatai Baburao Patil Institute of Pharmacy, Nanded, Maharashtra, India*

Publication history: Received on 14th October 2025; Revised on 29th October 2025; Accepted on 3rd November 2025

Article DOI: 10.69613/px3frb50

Abstract: Major Depressive Disorder (MDD), particularly its treatment-resistant form, represents a substantial burden on global public health, characterized by low remission rates with conventional monoaminergic pharmacotherapy. The paradigm shift toward glutamatergic modulation has identified the N-methyl-D-aspartate (NMDA) receptor as a critical target for rapid-acting antidepressants. Nitrous oxide (N_2O), an inhalational anesthetic utilized safely in medicine for nearly two centuries, has emerged as a potent antagonist of the NMDA receptor with demonstrated efficacy in ameliorating depressive symptoms. Accumulating evidence indicates that a single inhalation session can yield rapid antidepressant effects lasting significantly longer than the pharmacokinetic elimination of the gas. While early investigations utilized psychotomimetic concentrations comparable to anesthetic induction, recent dose-finding studies suggest that sub-anesthetic concentrations, specifically 25%, offer a favorable therapeutic index by maintaining antidepressant efficacy while significantly minimizing adverse effects such as nausea and dissociation. Beyond NMDA antagonism, the mechanism of action appears to involve complex interplay with the endogenous opioid system, GABAergic disinhibition, and downstream neuroplasticity signaling pathways, including Brain-Derived Neurotrophic Factor (BDNF) release. Current research prioritizes establishing optimal dosing protocols, mitigating risks associated with vitamin B12 oxidation, and determining the feasibility of nitrous oxide as a scalable, office-based intervention. The translation of this anesthetic agent into a psychiatric tool requires rigorous standardization of delivery methods and strict vigilance regarding metabolic contraindications.

Keywords: Nitrous oxide; Treatment-resistant depression; NMDA receptor antagonist; Glutamate; Rapid-acting antidepressants

1. Introduction

Treatment-Resistant Depression (TRD), generally defined as a failure to respond to at least two adequate trials of antidepressants from different classes, affects approximately one-third of patients diagnosed with Major Depressive Disorder [1]. This refractory condition is associated with significant functional impairment, economic burden, and elevated mortality rates. The temporal lag of weeks to months required for conventional monoaminergic antidepressants (SSRIs, SNRIs) to exert therapeutic effects contributes to prolonged morbidity and increased suicide risk [2]. Consequently, the identification of rapid-acting antidepressants (RAADs) has become a priority in neuropsychiatric research.

The discovery of the rapid antidepressant properties of ketamine, a dissociative anesthetic and N-methyl-D-aspartate (NMDA) receptor antagonist, validated the glutamatergic hypothesis of depression, shifting focus from monoamines to excitatory neurotransmission [3]. However, the psychotomimetic side effects, potential for urotoxicity, and abuse liability associated with ketamine necessitate strict monitoring and clinic-based restrictions (Risk Evaluation and Mitigation Strategies). This has prompted the search for alternative NMDA antagonists with superior tolerability profiles and easier routes of administration. Nitrous oxide (N_2O), commonly known as laughing gas, shares pharmacological similarities with ketamine but offers a distinct pharmacokinetic profile. Unlike ketamine, N_2O is a gas administered via inhalation, allowing for rapid onset and offset, which theoretically obviates the need for prolonged post-treatment monitoring. Although historically confined to anesthesia and dentistry, recent pilot studies and clinical trials have investigated the utility of N_2O in TRD. These investigations aim to delineate the precise neurobiological

* Corresponding author: Syed Ansar Ahmed

mechanisms ranging from glutamatergic blockade to downstream neurotrophic signaling and to establish an optimal dose-response relationship that maximizes efficacy while minimizing adverse events [4].

2. Pharmacodynamics and Neurobiological Mechanisms

2.1. NMDA Receptor Antagonism and The Disinhibition Hypothesis

The primary mechanism by which nitrous oxide exerts its antidepressant effect is hypothesized to be the non-competitive inhibition of NMDA receptors. The NMDA receptor is an ionotropic glutamate receptor crucial for synaptic plasticity and memory function. In the context of depression, excessive extrasynaptic glutamate activity is thought to lead to excitotoxicity and dendritic atrophy [5].

Table 1. Pharmacological and Mechanistic Comparison of Rapid-Acting NMDA Antagonists

Feature	Nitrous Oxide (N_2O)	Ketamine / Esketamine
Primary Target	NMDA Receptor (Non-competitive antagonist)	NMDA Receptor (Non-competitive antagonist)
Binding Site	Putative binding within the ion channel pore; exact site less defined than ketamine.	Phencyclidine (PCP) site within the ion channel pore.
Binding Mechanism	"Trapping" block characteristics are less pronounced; rapid dissociation.	"Trapping" block; requires channel to be open to bind and unbind.
Half-life ($t_{1/2}$)	~5 minutes (rapid pulmonary elimination).	~2.5 to 3 hours (hepatic metabolism via CYP450).
Opioid Interaction	Direct stimulation of endogenous opioid release (enkephalins/dynorphins) in periaqueductal gray.	Minimal direct opioid receptor interaction; some debate on downstream opioid system involvement.
Downstream Signaling	mTOR activation, BDNF upregulation, ERK1/2 pathway stimulation.	mTOR activation, BDNF upregulation, eukaryotic elongation factor 2 (eEF2) inhibition.

By blocking these receptors, particularly the GluN1 and GluN2 subunits, N_2O reduces excitatory transmission. Current models propose a "disinhibition hypothesis," suggesting that NMDA antagonists preferentially block receptors on GABAergic interneurons. This blockade reduces the inhibitory tone on excitatory pyramidal neurons, paradoxically leading to a surge in glutamate release in the medial prefrontal cortex (mPFC). This glutamate surge subsequently activates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, increasing the AMPA-to-NMDA throughput ratio. This shift is believed to trigger rapid synaptic potentiation, a mechanism shared with ketamine [6].



Figure 1. Mechanism of Action of N_2O - The Disinhibition Hypothesis

However, distinct differences exist in the binding kinetics. While ketamine acts as an open-channel blocker requiring channel activation to bind ("trapping" block), the specific binding dynamics of N_2O within the pore remain less structurally defined but result in a similar functional outcome: the rapid restoration of synaptic connectivity in mood-regulating circuits [7].

2.2. Downstream Neuroplasticity and Signaling Cascades

The immediate receptor-level events initiate a cascade of intracellular signaling pathways vital for neuronal health. NMDA antagonism by N_2O leads to the phosphorylation of the mammalian target of rapamycin (mTOR) and the subsequent upregulation of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus and prefrontal cortex [8]. BDNF is a critical protein for neurogenesis and the maintenance of dendritic spines.

Depressed states are consistently associated with reduced BDNF levels and hippocampal volume loss. The administration of N_2O appears to rapidly reverse these deficits, promoting structural plasticity within 24 hours of administration. Studies in rodent models have shown that N_2O exposure stimulates the ERK1/2 signaling pathway, which is essential for the transcription of immediate-early genes involved in synaptic remodeling [9]. This neurotrophic response distinguishes RAADs from conventional antidepressants, which may take weeks to induce similar genomic and structural changes.

2.3. The Opioidergic Component

Distinct from ketamine, nitrous oxide possesses intrinsic analgesic properties mediated partially through the endogenous opioid system. It stimulates the release of enkephalins and dynorphins in the periaqueductal gray matter, which then act on descending inhibitory pain pathways [10]. This opioidergic activity prompted investigations into whether the antidepressant effects of N_2O are sensitive to opioid blockade.

Preliminary data suggests that naltrexone, an opioid receptor antagonist, may attenuate some of the acute psychotropic effects of N_2O, implying that the endogenous opioid system contributes to the initial mood elevation. However, the sustained antidepressant effect observed days after treatment likely remains glutamate-dependent. This dual mechanism opioid modulation for acute relief and glutamatergic modulation for sustained plasticity may offer a unique therapeutic advantage over pure NMDA antagonists [11].

3. Clinical Efficacy in Treatment-Resistant Depression

3.1. Proof-of-Concept and Initial Findings

The first randomized, double-blind, crossover trial investigating inhaled nitrous oxide for TRD utilized a concentration of 50% N_2O mixed with 50% oxygen. This pivotal study demonstrated a significant reduction in the Hamilton Depression Rating Scale (HDRS-21) scores compared to placebo, with response rates approaching 20% within two hours and sustained improvement observed over 24 hours [12].

Patients in this cohort had failed an average of 4.5 antidepressant trials, highlighting the robustness of the response in a refractory population. The rapidity of symptom relief was notable, with some subjects reporting improvements during the inhalation session itself. Unlike placebo responders who often relapse quickly, the N_2O group demonstrated a separation from placebo that persisted, suggesting a biological drug effect rather than a psychological expectation effect [13].

Table 2. Summary of Pivotal Clinical Trials of Nitrous Oxide in Treatment-Resistant Depression

Study Author (Year)	Study Design	Sample Size (N)	Intervention Protocol	Findings
Nagele et al. (2015) [12]	Double-blind, randomized, crossover, placebo-controlled	20	Single session: 50% N_2O / 50% O_2 vs. Placebo (O_2 + N_2) for 1 hour.	Significant reduction in HDRS-21 scores at 2 hrs and 24 hrs post-treatment. Response rate ~20%. Evaluation of sustained effect limited to short-term.
Nagele et al. (2021) [14]	Phase 2, double-blind, randomized, parallel-group	24	Single session: 25% N_2O vs. 50% N_2O vs. Placebo for 1 hour.	Both 25% and 50% doses showed comparable antidepressant efficacy. The 25% dose had markedly fewer adverse events (AEs) than the 50% dose (AE rate: 25% dose = placebo levels).
Gu et al. (2022)	Open-label pilot study	30	Repeated sessions: 50% N_2O twice weekly for 2 weeks.	Repeated administration was feasible and tolerated. Cumulative antidepressant effects observed, suggesting utility of maintenance therapy.

3.2. Dose-Response Optimization: The 25% vs. 50% Debate

Following the initial success of 50% concentrations, concerns regarding adverse effects specifically nausea, vomiting, and psychotomimetic experiences prompted researchers to evaluate lower dosages. A subsequent large-scale trial compared the efficacy of 25% N_2O versus 50% N_2O and placebo. The results provided a critical turning point in the clinical application of the gas: the 25% concentration demonstrated antidepressant efficacy statistically comparable to the 50% dose but with a four-fold reduction in adverse events [14].

This finding suggests a ceiling effect for antidepressant efficacy at sub-anesthetic doses, where higher concentrations increase toxicity without enhancing therapeutic gain. The 25% protocol is particularly advantageous for outpatient settings, as it minimizes sedation and the need for antiemetic prophylaxis. Furthermore, the lower concentration significantly reduces the likelihood of dissociative side effects, making the treatment more acceptable to patients who may find the "trip" of ketamine or high-dose N_2O distressing [15].

Table 3. Risk-Benefit Profile of Different Nitrous Oxide Concentrations

Clinical Parameter	25% Concentration (Sub-anesthetic)	50% Concentration (Sedative/Analgesic)
Antidepressant Efficacy	High (Non-inferior to 50%)	High
Sedation Level	Minimal (Conscious sedation, fully responsive)	Moderate (May cause drowsiness, cognitive slowing)
Nausea/Vomiting Rate	Low (< 5%)	Moderate to High (> 20%)
Psychotomimetic Effects	Rare / Mild	Common (Dissociation, hallucinations, euphoria)
Recovery Time	Rapid (~15 minutes)	Moderate (~30–45 minutes)
Suitability for Outpatient	Excellent	Good (Requires longer monitoring)

3.3. Durability of Effect and Maintenance Strategies

A major challenge with RAADs is the transience of the therapeutic response. While a single infusion or inhalation provides relief for days to a week, relapse is common without maintenance treatment. Studies indicate that the antidepressant effects of a single N_2O session can persist for up to one week, necessitating repeated administration protocols for sustained remission [16].

Sequential administration strategies are currently under investigation to determine if cumulative neuroplasticity can lead to longer inter-treatment intervals. Some pilot data suggests that a course of treatments (e.g., twice weekly for 4 weeks) may extend the duration of remission, similar to induction protocols used in Electroconvulsive Therapy (ECT) or Transcranial Magnetic Stimulation (TMS) [17].

4. Safety Profile and Metabolic Considerations

4.1. Acute Adverse Effects

In the context of supervised medical administration, nitrous oxide is generally safe. However, the adverse event profile is dose-dependent. At 50% concentration, rates of nausea and vomiting can be substantial, leading to treatment discontinuation in a subset of patients [18]. Psychotomimetic side effects, including dissociation, hallucinations, and paranoid ideation, are also observed but are typically short-lived, resolving within minutes of gas cessation due to the rapid pulmonary elimination of N_2O [19].

This rapid offset serves as a significant logistical advantage over ketamine, which requires extended post-administration monitoring. Patients treated with 25% N_2O typically reach full recovery of psychomotor function within 15 to 30 minutes post-inhalation, potentially allowing for discharge without the stringent driving restrictions often applied to ketamine patients.

4.2. Vitamin B12 and Homocysteine Metabolism

The most significant safety concern regarding repeated nitrous oxide exposure is its interaction with Vitamin B12 (cobalamin). N_2O irreversibly oxidizes the cobalt ion in cobalamin from the +1 to the +3 valency state, rendering the enzyme methionine synthase inactive [20].

This enzyme is essential for the conversion of homocysteine to methionine and the subsequent synthesis of DNA and myelin. Acute inactivation is usually compensated for by hepatic stores of B12; however, in patients with borderline B12 deficiency, nutritional deficits, or genetic polymorphisms (such as MTHFR mutations), frequent chronic dosing can lead to hyperhomocysteinemia. Clinical consequences include megaloblastic anemia and subacute combined degeneration of the spinal cord [21]. Therefore, mandatory screening for B12 deficiency, folate levels, and potential supplementation is a requisite safety protocol for any longitudinal N_2O treatment program. Monitoring homocysteine and methylmalonic acid levels provides a more sensitive marker of functional B12 status than serum B12 levels alone [22].



Figure 2. Mechanism of B12 Inactivation

Table 4. Guidelines for Monitoring and Mitigating Metabolic Risks

Component	Rationale	Recommended Frequency
Baseline Screening	Identify pre-existing deficiency to prevent rapid neurological deterioration.	Prior to initiation of treatment.
Serum Vitamin B12	Direct measure of cobalamin stores. Note: Levels can be falsely normal; functional markers are superior.	Baseline and every 3 months during maintenance.
Homocysteine	Functional marker; accumulates when B12 is inactivated. High levels indicate metabolic stress.	Baseline and every 1–2 months during active treatment.
Methylmalonic Acid (MMA)	Highly specific functional marker for B12 deficiency.	If Homocysteine is elevated or B12 is borderline.
B12 Supplementation	Prophylactic replacement to counteract oxidation.	Oral or intramuscular supplementation recommended for chronic users or at-risk patients.
Contraindications	MTHFR mutations, severe anemia, existing neuropathy.	Strict exclusion criteria.

5. Comparative Analysis and Implementation Challenges

5.1. Nitrous Oxide vs. Ketamine and ECT

While Electroconvulsive Therapy (ECT) remains the gold standard for efficacy in TRD, its invasive nature, requirement for general anesthesia, and cognitive side effects limit its use. Nitrous oxide occupies a niche similar to ketamine but with distinct logistical advantages. Unlike intravenous (IV) ketamine, which requires vascular access and infusion pumps, N_2O is non-invasive.

Compared to intranasal esketamine, N_2O has a faster washout period. Ketamine treatment typically requires a 2-hour observation period due to dissociative effects and blood pressure fluctuations. In contrast, the rapid elimination of N_2O could allow for "chair time" of less than one hour, significantly increasing clinic throughput and reducing patient burden [23]. However, ketamine currently has a more robust evidence base regarding long-term maintenance and anti-suicidal effects compared to the nascent data on N_2O.

5.2. Barriers to Clinical Implementation

Despite the promising data, several barriers impede the widespread adoption of N_2O for depression. The "laughing gas" stigma associated with recreational abuse may trivialize the treatment in the eyes of patients or regulatory bodies. Furthermore, chronic exposure to waste anesthetic gas presents an occupational health hazard for healthcare providers, necessitating facilities equipped with proper scavenging systems and ventilation, which may not be standard in outpatient psychiatric clinics [24].

Table 5. Operational Comparison of Interventional Psychiatries

Feature	Nitrous Oxide (N_2O)	IV Ketamine	Intranasal Esketamine	ECT
Route of Admin	Inhalation (Mask)	Intravenous (Infusion)	Intranasal (Spray)	Electrical Stimulation
Invasiveness	Non-invasive	Invasive (IV access)	Non-invasive	Minimally Invasive (General Anesthesia)
Onset of Action	Minutes to Hours	Hours	Hours	Days (requires multiple sessions)
Duration of Session	~60 minutes (Treatment + Recovery)	~120 minutes (40m Infusion + Monitoring)	~120 minutes (Monitoring mandatory)	~60 minutes (Pre-op + Procedure + Recovery)
Cognitive Side Effects	Minimal post-recovery	Dissociation, transient cognitive fog	Dissociation, dizziness	Memory loss (retrograde/anterograde)
Cost / Resource Use	Low (Gas + Mask)	High (IV pump, nursing staff)	High (Drug cost)	Very High (Anesthesiologist, OR suite)

There is also the challenge of preventing misuse. While the medical setting controls administration, the potential for patients to seek recreational sources for "self-medication" must be addressed through psychoeducation. Finally, reimbursement models for inhalational psychiatric treatments are currently undefined, posing an economic hurdle for private practice implementation [25].

6. Conclusion

Nitrous oxide represents a promising evolution in the pharmacotherapy of Treatment-Resistant Depression, offering a rapid-acting mechanism distinct from the monoaminergic hypothesis. The convergence of clinical data suggests that lower concentrations, specifically 25%, provide an optimal balance between antidepressant efficacy and tolerability, circumventing the adverse effects that limit the utility of higher anesthetic doses. While the precise interplay between NMDA antagonism, opioid release, and neurotrophic signaling requires further elucidation, the ability of N_2O to induce rapid remission in refractory cases is clinically significant. The inherent risks associated with cobalamin oxidation necessitate rigorous patient selection and monitoring protocols. As research progresses toward standardized maintenance regimens, nitrous oxide holds the potential to become a widely accessible, scalable intervention for acute depressive crises, bridging the gap between conventional medication and more invasive procedural therapies.

References

[1] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.

[2] Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69(6):946-58.

[3] Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.

[4] Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460-3.

[5] Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77.

[6] Miller OH, Yang L, Hall BJ, Wang X. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2017;546(7656):46-51.

[7] Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. Anesth Prog. 2007;54(1):9-18.

[8] Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64.

[9] Kohtala S. Ketamine-like rapid-acting antidepressants: From mechanism to clinical practice? Basic Clin Pharmacol Toxicol. 2021;128(2):236-48.

[10] Gillman MA, Lichtigfeld FJ. The opiate system in nitrous oxide analgesia. S Afr Med J. 1986;69(2):94-6.

[11] Emmanouil DE, Quock RM. Opioid-dependent analgesic effects of nitrous oxide in mice. Eur J Pharmacol. 2004;504(1-2):57-60.

[12] Nagele P, Duma A, Kopec Koziol M, Steinliner MA, Gospodarev V, Hussain S, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry. 2015;78(1):10-8.

[13] Zorumski CF, Conway CR. Nitrous Oxide: An Old Gas, a New Mechanism, a New Indication? Biol Psychiatry. 2015;78(1):2-3.

[14] Nagele P, Palanca BJ, Gott B, Brown F, Barnes L, Nguyen T, et al. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med. 2021;13(597):eabe1376.

[15] Zorumski CF, Nagele P, Conway CR. Multimodal NMDA Receptor Antagonists for Treatment-Resistant Depression. Neuropsychopharmacology. 2016;41(1):364-5.

[16] Nagele P. Nitrous oxide in the treatment of depression. Curr Opin Anaesthesiol. 2022;35(4):463-7.

[17] Guidi J, Fava G. Managing treatment-resistant depression: the importance of a sequential approach. Psychiatr Clin North Am. 2018;41(2):215-28.

[18] Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology. 2007;107(2):221-31.

[19] Broussard H, Broussard G. Nitrous Oxide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

[20] Chanarin I. The effects of nitrous oxide on cobalamins, folates, and related events. Crit Rev Toxicol. 1982;10(3):179-213.

[21] Weimann J. Toxicity of nitrous oxide. Best Pract Res Clin Anaesthesiol. 2003;17(1):47-61.

[22] Garakani A, Jaffe RJ, Savla D, Welch AK, Protin CA, Bryson EO, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the literature. Am J Addict. 2016;25(5):358-69.

[23] Zorumski CF, Conway CR, Paul SM. Ketamine and N-methyl-D-aspartate receptors: a new era in the pharmacology of depression? Biol Psychiatry. 2016;80(5):336-7.

[24] Byhahn C, Wilke HJ, Westphal K. Occupational exposure to volatile anaesthetics: epidemiology and approaches to reducing the problem. CNS Drugs. 2001;15(3):197-215.

[25] Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405.